Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E45.10 EPS (ttm)1.40 Insider Own0.04% Shs Outstand2.75B Perf Week-1.40%
Market Cap173.74B Forward P/E15.10 EPS next Y4.19 Insider Trans-29.19% Shs Float2.74B Perf Month-2.38%
Income3.92B PEG6.80 EPS next Q0.84 Inst Own75.30% Short Float0.63% Perf Quarter5.35%
Sales39.81B P/S4.36 EPS this Y-10.00% Inst Trans-0.94% Short Ratio1.61 Perf Half Y2.43%
Book/sh14.54 P/B4.35 EPS next Y10.03% ROA4.00% Target Price68.75 Perf Year22.88%
Cash/sh5.31 P/C11.92 EPS next 5Y6.64% ROE9.20% 52W Range50.88 - 66.32 Perf YTD8.27%
Dividend1.88 P/FCF47.76 EPS past 5Y-7.00% ROI6.20% 52W High-4.59% Beta0.84
Dividend %2.97% Quick Ratio1.50 Sales past 5Y-3.70% Gross Margin65.60% 52W Low24.38% ATR0.78
Employees68000 Current Ratio1.80 Sales Q/Q-1.00% Oper. Margin13.50% RSI (14)40.62 Volatility1.13% 1.13%
OptionableYes Debt/Eq0.62 EPS Q/Q-162.20% Profit Margin9.80% Rel Volume0.89 Prev Close63.50
ShortableYes LT Debt/Eq0.61 EarningsFeb 02 BMO Payout130.00% Avg Volume10.70M Price63.28
Recom2.30 SMA20-2.59% SMA50-0.42% SMA2004.36% Volume9,459,658 Change-0.35%
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Mar-24-17 03:40AM  Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
Mar-23-17 10:00AM  Merck Closes Acquisition of Controlling Stake in Vallee S.A
08:59AM  The Supreme Court could fundamentally change America's broken patent system
Mar-22-17 04:05PM  Merck Animal Health Completes Acquisition of Vallée S.A. Business Wire
12:24PM  Merck must face renewed Fosamax warning claims -U.S. appeals court Reuters
11:47AM  Merck Osteoporosis Drug Linked to Thigh Fractures at Investopedia
10:37AM  Durvalumab and Tagrisso May Boost AstraZenecas Revenues in 2017
08:48AM  U.S. appeals court revives Fosamax warning claims against Merck
Mar-21-17 06:05PM  Japan May Prove to Be Strong Growth Driver for AstraZeneca in 2017
09:30AM  The Zacks Analyst Blog Highlights: Merck, General Electric, MasterCard and NVIDIA
Mar-20-17 04:10PM  Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal
10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
09:41AM  Pfizer, Merck KGaA Delay Lung Cancer Drug Trial Outcome at Investopedia
Mar-17-17 09:27AM  Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
07:38AM  A Look at Opdivos Performance in 2016
Mar-16-17 02:54PM  Merck & Co., Inc. (MRK) Sued By Numerous Plaintiffs Over Harm Caused By Its Zostavax Drug at Insider Monkey
Mar-15-17 03:05PM  Mercks Zostavax Faces Lawsuits over Drug Safety at Investopedia
02:53PM  Merck Could Be Nearing This Rival With Another Keytruda Approval
02:13PM  Pfizers Cash Flow Stamina versus Mercks Ambitious R&D
12:17PM  Merck Blood Cancer Drug Keytruda Wins FDA Nod at Investopedia
11:35AM  After Soaring to $150, Can Incyte Stir Up More Upside?
10:57AM  Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication
10:55AM  Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
Mar-14-17 06:22PM  Merck's Keytruda wins FDA nod for treating blood cancer Reuters
05:05PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy Business Wire
04:43PM  Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer Business Wire
07:39AM  Why Did the Healthcare Sector Fall on March 13?
Mar-13-17 04:05PM  U.S. stocks little changed ahead of expected rate hike at MarketWatch
04:01PM  Intel, GE Weigh on DJIA Monday
11:55AM  Lilly, Merck, Allergan Top Analyst's View For 2017 Pharma
10:37AM  Johnson & Johnsons Business Segment Performance
07:37AM  Johnson & Johnsons Valuation Compared to Its Peers
Mar-10-17 02:13PM  Dear Gilead: Buy Something Anything Analyst Pleads
12:36PM  Jobs report beats expectations
11:32AM  Adam Feuerstein Talks Vulnerable Pharmaceuticals, Drug Pricing Under Trump
08:55AM  Short Sellers Back Off Major Pharma
07:51AM  How Incyte Stock Became a Bull Market Star for Biotech Investors
05:32AM  New Merck Technology Aims to Further Optimize Embryo Incubation and Assessment CNW Group
Mar-09-17 04:55PM  Will Merck, Glaxo Undercut Gilead's Next 'Mount Everest' Drug?
11:41AM  Incyte Corporation at the Cowen Healthcare Conference: 4 Things You'll Want to Know at Motley Fool
10:27AM  Bank shares jump in Europe as Draghi plays down deflationary risks at MarketWatch
03:40AM  Merck sees surge in fourth-quarter net profit
12:32AM  Merck CEO: Not seen details of Trump's health care plan
Mar-08-17 04:22PM  This Pharma Firm Is Beating The Pack In Getting Drugs To Market
12:39PM  Chaos Is Biggest Threat to Wednesday's Vote on Repealing Obamacare
11:11AM  GLOBAL MARKETS-Dollar, stocks rise as data boosts Fed hike bets Reuters
10:35AM  Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates
10:30AM  Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA
08:04AM  Forget the Distractions: Bristol-Myers Squibb Is a Bargain at Motley Fool
06:58AM  US Indexes Lower on Energy Stock Losses
12:32AM  Race Tightens for Next Wave of Cancer Drugs at The Wall Street Journal
Mar-07-17 11:17PM  Stocks: Ready for Trump rally rebound or third straight down day and bigger retreat from Dow 21K? at bizjournals.com
08:25PM  Trump's Twitter tantrums a pharma buying opportunity
06:41PM  Cramer: Why Trumps Twitter tantrums on pharma are your b...
06:16PM  Cramer: Why Trumps Twitter tantrums on pharma are your buying opportunity at CNBC
05:07PM  3 large-cap buys to play strength in health care: Ross
04:01PM  Chevron, Verizon Sink DJIA on Tuesday
03:50PM  Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices
02:13PM  GLOBAL MARKETS-Stocks slip, U.S. dollar firm on Fed outlook Reuters
01:06PM  Stock market loses ground as energy shares weigh at MarketWatch
12:53PM  Trump endorses House Republican healthcare plan, obstacles remain Reuters
11:51AM  GLOBAL MARKETS-Wall Street slips, U.S. dollar firm on Fed outlook Reuters
11:34AM  Trump Tweets And Drug Stocks Fall at Barrons.com
10:36AM  Ten stocks to watch with focus on Obamacare, drug prices; Dow Jones dips; Snap slides 10 percent early at bizjournals.com
07:54AM  Early movers: DKS, MIK, NAV, PFE, AET, CSX, & more at CNBC
03:11AM  Why Is Merck (MRK) Up 3.7% Since the Last Earnings Report?
Mar-06-17 12:23PM  Race Tightens for Next Wave of Cancer Drugs at The Wall Street Journal
09:50AM  Where Merck and Pfizers Type 2 Diabetes Treatment Can Go From Here
09:33AM  UPDATE: Dynavax shares reverse premarket losses to open flat at MarketWatch
09:30AM  The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi
09:19AM  Germany to scrap plan to lower prices of new drugs-lawmakers Reuters
09:10AM  What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
08:00AM  Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes Business Wire
07:39AM  5 FDA Decisions to Watch Out for in Mar 2017
Mar-05-17 03:14PM  US Market Indexes Higher for the Week
Mar-04-17 01:04PM  MERCK & CO., INC. Financials
Mar-03-17 05:21PM  What's in Store for Immune Design (IMDZ) in Q4 Earnings?
04:10PM  Stocks extend weekly winning streaks as rate hike looms at MarketWatch
09:40AM  Agilent Technologies Should 'Ace' This Test
08:33AM  Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug
08:22AM  Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
07:33AM  Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot
Mar-02-17 06:04PM  Is This The Best Biotech Play for 2017?
11:45AM  Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock
Mar-01-17 06:47PM  Could pharma sector roar even higher? Cramer checks the c...
06:42PM  Cramers charts uncover 4 pharma stocks ready to explode ...
06:36PM  Cramers charts uncover 4 pharma stocks ready to explode higher at CNBC
05:15PM  Drugs stocks shrug off Trump warning
05:07PM  [$$] Drug Companies Block Shareholders' Voting on Price Transparency at The Wall Street Journal
04:22PM  Tesaro Eyes Immuno-Oncology As AstraZeneca, Clovis Loom: Analyst
01:02PM  Big Pharma Pushes Back on Drug-Price Complaints at Investopedia
10:37AM  How Gileads Liver Disease Drugs Portfolio Performed
10:36AM  AstraZenecas Symbicort: Dominant Player in Inhaler Segment
10:04AM  [$$] Cancer Test Makers Raise Nearly $1 Billion at The Wall Street Journal
09:06AM  Emerging Markets Expected to Be AstraZenecas Key Growth Driver
07:38AM  How Gileads Revenue Trended in 2016
07:37AM  AstraZenecas New Products May Offer 2017 Growth Opportunities
07:36AM  Label Expansion Expected to Boost Keytrudas 2017 Revenue
Feb-28-17 07:27PM  Cramer Remix: How drug stocks fulfilled their destiny wit...
07:21PM  Cramer Remix: How drug stocks fulfilled their destiny without Trump at CNBC
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale64.732,954191,22711,675Feb 15 11:30 AM
RUSSO PATRICIA FDirectorFeb 08Option Exercise35.195,000175,95018,148Feb 09 12:52 PM
RUSSO PATRICIA FDirectorFeb 08Sale64.425,000322,12113,148Feb 09 12:52 PM
WEEKS WENDELL PDirectorFeb 06Option Exercise51.865,000259,3005,100Feb 06 03:35 PM
WEEKS WENDELL PDirectorFeb 06Sale64.515,000322,542100Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Option Exercise32.5115,000487,65016,000Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Option Exercise59.0977,9594,606,471142,239Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Option Exercise34.3536,3351,248,17336,335Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Option Exercise35.195,000175,9505,100Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Sale63.425,000317,100100Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Sale63.7336,3352,315,6990Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Sale63.9691,9595,881,25250,280Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Sale63.6915,000955,4061,000Feb 06 03:35 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM